{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:48:28Z","timestamp":1790401708288,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1016\/j.amjmed.2011.12.018","type":"journal-article","created":{"date-parts":[[2012,7,24]],"date-time":"2012-07-24T16:01:11Z","timestamp":1343145671000},"page":"817-825","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists"],"prefix":"10.1016","volume":"125","author":[{"given":"Saurav","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaim","family":"Moeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwaseyi","family":"Bolorunduro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Lichstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Moskovits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debabrata","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.amjmed.2011.12.018_bib1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.amjmed.2011.12.018_bib2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.amjmed.2011.12.018_bib3","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"issue":"1 Pt 2","key":"10.1016\/j.amjmed.2011.12.018_bib4","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1161\/01.HYP.31.1.451","article-title":"Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats","volume":"31","author":"Rocha","year":"1998","journal-title":"Hypertension"},{"issue":"19","key":"10.1016\/j.amjmed.2011.12.018_bib5","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","article-title":"Eplerenone: cardiovascular protection","volume":"107","author":"Brown","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.amjmed.2011.12.018_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"issue":"8","key":"10.1016\/j.amjmed.2011.12.018_bib7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"issue":"3","key":"10.1016\/j.amjmed.2011.12.018_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s10557-006-8282-y","article-title":"Cost-effectiveness of eplerenone in patients with left ventricular dysfunction after myocardial infarction\u2014an analysis of the EPHESUS study from a Swiss perspective","volume":"20","author":"Szucs","year":"2006","journal-title":"Cardiovasc Drugs Ther"},{"issue":"2","key":"10.1016\/j.amjmed.2011.12.018_bib9","first-page":"217","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"10.1016\/j.amjmed.2011.12.018_bib10","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]","year":"2011"},{"issue":"7","key":"10.1016\/j.amjmed.2011.12.018_bib11","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.amjmed.2011.12.018_bib12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1136\/bmj.326.7387.472","article-title":"Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysis","volume":"326","author":"Song","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.amjmed.2011.12.018_bib13","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ahj.2005.03.032","article-title":"Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction","volume":"150","author":"Di Pasquale","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2011.12.018_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","article-title":"Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction [see comment]","volume":"141","author":"Modena","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2011.12.018_bib15","first-page":"643","article-title":"Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study [Spanish]","volume":"125","author":"Rodriguez","year":"1997","journal-title":"Rev Med Chil"},{"key":"10.1016\/j.amjmed.2011.12.018_bib16","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.12.018_bib17","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [see comment] [erratum appears in N Engl J Med. 2003;348:2271]","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2011.12.018_bib18","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/eurheartj\/ehi023","article-title":"Spironolactone improves lung diffusion in chronic heart failure","volume":"26","author":"Agostoni","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2011.12.018_bib19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1536\/jhj.44.681","article-title":"Effects of spironolactone and metoprolol on QT dispersion in heart failure","volume":"44","author":"Akbulut","year":"2003","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.amjmed.2011.12.018_bib20","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0002-9149(99)80353-1","article-title":"Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease","volume":"76","author":"Barr","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2011.12.018_bib21","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2459\/JCM.0b013e3281053a9a","article-title":"Baseline characteristics of patients recruited in the AREA IN-CHF study (Antiremodelling Effect of Aldosterone Receptors Blockade with Canrenone in Mild Chronic Heart Failure)","volume":"8","author":"Boccanelli","year":"2007","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.amjmed.2011.12.018_bib22","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2007.03.062","article-title":"Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure","volume":"50","author":"Chan","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2011.12.018_bib23","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S0735-1097(02)01965-4","article-title":"Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure","volume":"40","author":"Cicoira","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2011.12.018_bib24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cardfail.2006.11.015","article-title":"Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure","volume":"13","author":"Gao","year":"2007","journal-title":"J Card Fail"},{"issue":"Suppl 1","key":"10.1016\/j.amjmed.2011.12.018_bib25","first-page":"188A","article-title":"Eplerenone, a novel selective aldosterone receptor antagonist (SARA): dose finding study in patients with heart failure","volume":"15","author":"Pitt","year":"1999","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2011.12.018_bib27","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","article-title":"Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES])","volume":"78","year":"1996","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2011.12.018_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"EPHESUS Investigators","volume":"46","author":"Pitt","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.amjmed.2011.12.018_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta14240","article-title":"A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure","volume":"14","author":"McKenna","year":"2010","journal-title":"Health Technol Assess"},{"issue":"10","key":"10.1016\/j.amjmed.2011.12.018_bib30","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00019053-200523100-00008","article-title":"Eplerenone: a pharmacoeconomic review of its use in patients with post-myocardial infarction heart failure","volume":"23","author":"Croom","year":"2005","journal-title":"Pharmacoeconomics"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934312001635?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934312001635?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:57:39Z","timestamp":1757581059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934312001635"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["S0002934312001635"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2011.12.018","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2012,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2011.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}